The Personalized Medicine Coalition: goals and strategies.

Edward Abrahams, Geoffrey S Ginsburg, Mike Silver
{"title":"The Personalized Medicine Coalition: goals and strategies.","authors":"Edward Abrahams,&nbsp;Geoffrey S Ginsburg,&nbsp;Mike Silver","doi":"10.2165/00129785-200505060-00002","DOIUrl":null,"url":null,"abstract":"<p><p>The concept of personalized medicine--that medical care can be tailored to the genomic and molecular profile of the individual--has repercussions that extend far beyond the technology that makes it possible. The adoption of personalized medicine will require changes in healthcare infrastructure, diagnostics and therapeutics business models, reimbursement policy from government and private payers, and a different approach to regulatory oversight. Personalized medicine will shift medical practices upstream from the reactive treatment of disease, to proactive healthcare management including screening, early treatment, and prevention, and will alter the roles of both physician and patient. It will create a greater reliance on electronic medical records and decision support systems in an industry that has a long history of resistance to information technology. Personalized medicine requires a systems approach to implementation. But in a healthcare economy that is highly decentralized and market driven, it is incumbent upon the stakeholders themselves to advocate for a consistent set of policies and legislation that pave the way for the adoption of personalized medicine. To address this need, the Personalized Medicine Coalition (PMC) was formed as a nonprofit umbrella organization of pharmaceutical, biotechnology, diagnostic, and information technology companies, healthcare providers and payers, patient advocacy groups, industry policy organizations, major academic institutions, and government agencies. The PMC provides a structure for achieving consensus positions among these stakeholders on crucial public policy issues, a role which will be vital to translating personalized medicine into widespread clinical practice. In this article, we outline the goals of the PMC, and the strategies it will take to foster communication, debate, and consensus on issues such as genetic discrimination, the reimbursement structures for pharmacogenomic drugs and diagnostics, regulation, physician training and medical school curricula, and public education.</p>","PeriodicalId":72171,"journal":{"name":"American journal of pharmacogenomics : genomics-related research in drug development and clinical practice","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2165/00129785-200505060-00002","citationCount":"124","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of pharmacogenomics : genomics-related research in drug development and clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2165/00129785-200505060-00002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 124

Abstract

The concept of personalized medicine--that medical care can be tailored to the genomic and molecular profile of the individual--has repercussions that extend far beyond the technology that makes it possible. The adoption of personalized medicine will require changes in healthcare infrastructure, diagnostics and therapeutics business models, reimbursement policy from government and private payers, and a different approach to regulatory oversight. Personalized medicine will shift medical practices upstream from the reactive treatment of disease, to proactive healthcare management including screening, early treatment, and prevention, and will alter the roles of both physician and patient. It will create a greater reliance on electronic medical records and decision support systems in an industry that has a long history of resistance to information technology. Personalized medicine requires a systems approach to implementation. But in a healthcare economy that is highly decentralized and market driven, it is incumbent upon the stakeholders themselves to advocate for a consistent set of policies and legislation that pave the way for the adoption of personalized medicine. To address this need, the Personalized Medicine Coalition (PMC) was formed as a nonprofit umbrella organization of pharmaceutical, biotechnology, diagnostic, and information technology companies, healthcare providers and payers, patient advocacy groups, industry policy organizations, major academic institutions, and government agencies. The PMC provides a structure for achieving consensus positions among these stakeholders on crucial public policy issues, a role which will be vital to translating personalized medicine into widespread clinical practice. In this article, we outline the goals of the PMC, and the strategies it will take to foster communication, debate, and consensus on issues such as genetic discrimination, the reimbursement structures for pharmacogenomic drugs and diagnostics, regulation, physician training and medical school curricula, and public education.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
个性化医疗联盟:目标和策略。
个性化医疗的概念——医疗护理可以根据个人的基因组和分子特征进行定制——其影响远远超出了使其成为可能的技术。采用个性化医疗将需要改变医疗基础设施、诊断和治疗业务模式、政府和私人付款人的报销政策,以及不同的监管方法。个性化医疗将使医疗实践从疾病的被动治疗转向包括筛查、早期治疗和预防在内的主动医疗管理,并将改变医生和患者的角色。这将使一个长期抵制信息技术的行业更加依赖电子病历和决策支持系统。个性化医疗需要一个系统的方法来实施。但是,在高度分散和市场驱动的医疗保健经济中,利益相关者自己有责任倡导一套一致的政策和立法,为采用个性化医疗铺平道路。为了满足这一需求,个性化医疗联盟(PMC)成立了,这是一个由制药、生物技术、诊断和信息技术公司、医疗保健提供者和付款人、患者权益团体、行业政策组织、主要学术机构和政府机构组成的非营利伞形组织。PMC为这些利益相关者在关键的公共政策问题上达成共识立场提供了一个结构,这对于将个性化医疗转化为广泛的临床实践至关重要。在本文中,我们概述了PMC的目标,以及它将采取的策略,以促进在遗传歧视、药物基因组学药物和诊断的报销结构、监管、医生培训和医学院课程以及公众教育等问题上的沟通、辩论和共识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Towards molecular medicine: a case for a biological periodic table. Genetic testing in Crohn disease: utility in individualizing patient management. Identifying DNA methylation biomarkers of cancer drug response. The Autism Genome Project: goals and strategies. Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1